INGENIA Therapeutics is a clinical-stage biotech company pioneering
innovative therapies to restore vascular health.

We are committed to the discovery and development of therapeutic
antibody candidates for patient populations suffering from
microvascular disorders and progressive chronic diseases.

We use our deep knowledge and commitment to endothelial
biology to innovate and find new solutions where none exist.

We focus on the treatment of damaged capillary-associated
indications with high unmet clinical needs. We have exclusive global
rights to develop therapeutic antibody candidates for restoring damaged
capillaries to their healthy state by modulating endothelial cell signaling
pathways to recover damaged capillary functions.

We aim to be a global leader in developing next-generation
therapeutics to protect and restore the microvasculature.